AUTHORS
Eytan M Stein I, MD, Ghayas C. Issa, MD2, Craig Freyer, PharmD, BCOP3, Angela R. Smith, MD4, Li Yu, PhD5, Paul J. Shami, MD6, Ibrahim Aldoss, MD7
AFFILIATIONS
1 Memorial Sloan Kettering Cancer Center, New York, New York, United States
2 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
3 Syndax Pharmaceuticals, Inc., New York, New York, United States
4 Syndax Pharmaceuticals, Inc., New York, New York, United States
5 Syndax Pharmaceuticals, Inc., New York, New York, United States
6 Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah, United States
7 City of Hope National Medical Center, Duarte, California, United States
ABSTRACT
Background: Therapy-related acute myeloid leukemia (t-AML) can occur after cytotoxic treatment (eg, chemotherapy or radiation) for unrelated malignant or non-malignant diseases and represents a complex and challenging disease setting. KMT2A rearrangements (KMT2Ar) are often identified in patients with t-AML and are associated with aggressive disease and high relapse rates. Median overall survival for patients with KMT2Ar t-AML is significantly shorter than de novo KMT2Ar AML. Revumenib, a first-in-class, oral, potent, and selective inhibitor of the menin-KMT2A interaction, is used for the treatment of relapsed/refractory (R/R) AML harboring an NPM1 mutation or R/R acute leukemia with a KMT2A translocation in adult and pediatric patients 1 year and older. This analysis evaluates the efficacy and safety of revumenib in patients with R/R KMT2Ar t-AML using pooled data from the AUGMENT-101 clinical trial (NCT04065399) and an expanded access program (EAP; NCT05918913).
Methods: Patients in phase 1 of AUGMENT-101 received revumenib at various dose levels based on escalation rules, while patients in phase 2 of AUGMENT-101 and the EAP received the recommended phase 2 dose (160 mg with a strong CYP3A4 inhibitor [270 mg without]; 95 mg/m2 if <40 kg) q12h orally in 28-day cycles (or last tolerated dose received on study prior to transfer to the EAP). Patients were included in the response-evaluable population if they had KMT2Ar, ≥1 dose of revumenib and ≥1 disease response assessment. EAP disease assessments were performed until composite complete remission (CRc) was reached; no further response data were required. Responses were investigator-assessed in both studies. Assessments relevant to this analysis included rate of complete remission (CR)/CR with partial hematologic recovery (CRh), overall response rate (ORR), CRc rate, time to response, duration of response, and safety/tolerability. Measurable residual disease (MRD) negativity was analyzed locally by flow cytometry.
Results: In total, 24 patients (AUGMENT-101, n=14, data cutoff 19Feb2026; EAP, n=10, data cutoff 25Nov2025) were included in this analysis. Overall, median (range) age was 37 years (6–72); 5/24 (21%) patients were <18 years of age, 17 (71%) were 18–64 years, and 2 (8%) were ≥65 years. Most patients had an ECOG PS score ≥1 (14 [58%] patients). Patients received a median (range) of 2 prior lines of treatment (1–6), with 9 (38%) patients receiving ≥3 prior lines; 21 (88%) received prior intensive chemotherapy, 19 (79%) received prior venetoclax, and 12 (50%) had prior hematopoietic stem cell transplant (HSCT). Median (range) duration of follow-up was 12.3 mo (3.1–59.8) in AUGMENT-101 and 3.5 mo (0.8–12.3) in the EAP.
In the response-evaluable population, the ORR was 78.3% (18/23; 95% CI 56.3–92.5), the CRc rate was 47.8% (11/23; 95% CI 26.8–69.4), the CR/CRh rate was 30.4% (7/23; 95% CI 13.2–52.9), and the CR rate was 21.7% (5/23; 95% CI 7.5–43.7). Six patients proceeded to HSCT and 2 resumed revumenib as maintenance after transplant. The proportion of CRc responders estimated to remain in CRc at 3 and 6 mo was 80.0% (95% CI 40.9–94.6) and 50.0% (95% CI 18.4–75.3), respectively. Median time to first CRc was 1.1 mo (range, 0.9–5.6). Of those who achieved CRc and had MRD testing (n=11), 8 (72.7%) patients were MRD negative.
Grade ≥3 treatment-emergent adverse events (TEAEs) occurred in 21/24 (88%) patients overall, and 14/24 (58%) patients had grade ≥3 revumenib-related TEAEs; none led to treatment discontinuation. Serious adverse events occurred in 14/24 (58%) patients. Grade ≥3 QTcF prolongation occurred in 4/24 (17%) patients; all were grade 3. Grade ≥3 differentiation syndrome (DS) occurred in 7/24 (29%) patients; all were grade 3. No patients in this analysis discontinued revumenib due to QTcF prolongation or DS. One TEAE led to death (bacterial infection), not related to revumenib.
Conclusions: Revumenib demonstrated rapid, durable, and clinically meaningful antileukemic activity in heavily pretreated patients with R/R KMT2Ar t-AML in a pooled analysis of patients treated in AUGMENT-101 and the EAP. The safety profile was consistent with previous reports and revealed no new safety signals. These findings support revumenib as an active and generally well tolerated therapeutic option for patients with R/R KMT2Ar t-AML, a high-risk population with historically poor outcomes and limited treatment options.
DISCLOSURES
Eytan M Stein I, MD: Eisai, Bristol Myers Squibb - Research Funding; Novartis, PinotBio, Janssen, Bristol Myers Squibb, Agios Pharmaceuticals, Jazz Pharmaceuticals, Menarini, Genentech, Genesis, AbbVie, Neoleukin Corporation, Gilead Sciences, Syndax Pharmaceuticals Inc., OnCusp Therapeutics, CTI BioPharma, Foghorn Therapeutics, Servier Laboratories, Calithera Biosciences, Daiichi Sankyo, Aptose Biosciences, Syros, Astellas Pharma, Ono Pharma, Blueprint Medicines; Epizyme Inc., Cellectis - Consultancy (Includes expert testimony)